Optieum Biotechnologies Inc. has developed an innovative technology known as the Eumbody System, which focuses on the efficient production of chimeric antigen receptors (CARs) for CAR-T cell therapy. This system utilizes a single-chain variable fragment (scFv) library to create a CAR library tailored to specific cancer types. The Eumbody System enables the screening of CAR-T cells that exhibit enhanced therapeutic effects compared to traditional CAR-T cells, making it a promising approach for treating refractory cancers, autoimmune diseases, and infections.

The company is dedicated to leveraging its foundational technology to deliver optimal pharmaceutical solutions for patients suffering from difficult-to-treat conditions. By focusing on the development of CAR-T cell therapies with robust anti-tumor effects, Optieum Biotechnologies aims to contribute significantly to the field of biopharmaceuticals and improve treatment outcomes for various diseases.

Japan

We are driving the evolution of next-generation CAR-T cell therapy with precision-engineered CAR constructs. Our CAR discovery engine focuses on optimizing the binding domain of CAR to enhance immune cell function, delivering robust therapeutic efficacy. Optieum is pushing the boundaries of solid tumor treatment powered by next-generation CAR constructs.

454 Shitsukawa, Toon-shi, Ehime 791-0204, JP

Optieum Biotechnologies Inc.

Company Details